In just the last 10 years, biopharmaceutical supply chains have changed dramatically. The single-source manufacturing model is becoming much rarer, making way for multi-enterprise manufacturing collaborations and partnerships to better meet the changing needs of the...
Emerson offers an integrated Spectral PAT solution for DeltaV, allowing manufacturers to pursue closed-loop control (and real-time quality assessments) using in-line spectroscopic instruments.
The days of maintaining paper records across the life sciences development and production pipeline are gone. Today’s regulatory requirements, not to mention the complexity of new treatments, requires organization that can only be provided electronically. However,...
There can be little question that Industry 4.0 technologies are reshaping the way life sciences companies operate. In the wake of the rapid development of vaccines during the COVID-19 pandemic, more facilities than ever are being “born digital.” Some of these...
On Monday at the Emerson Exchange Users’ Conference, Emerson’s Michalle Adkins and AbbVie’s Jeff Ziolkowski moderated a panel with Fujifilm’s Soren Skerris, Takeda’s Dr. Nina Schwalb, Eli Lilly’s James Weber, and Emerson’s Christian Berg. The experts shared the...
While the idea of adding costs to a food and beverage or pharmaceutical industry process like Clean-in-Place/Steam-in-Place (CIP/SIP) has not traditionally been an easy decision, in today’s industrial environment that has changed. With the retirement of experts, the...
Pollutants are produced by industrial emissions, automobile exhaust, and household waste. As well as chemical gases such as NOx, fluorocarbons are also present. With CO2 and methane, they cause acid rain, sick house syndrome, depletion of the ozone layer, and, of course, climate change.
The life sciences marketplace is changing faster than nearly any other industry. Gone are the days when companies focus on a single treatment to drive their entire business. Today’s life sciences manufacturers are challenged to bring new treatments to the marketplace...
Christian Berg describes some solutions and technologies which facilitate the pursuit of the adaptive plant for manufacturers in the Life Sciences industry, as defined by the BioPhorum Digital Plant Maturity Model.
In a Pharma Focus Asia webinar, Pursuing the Adaptive Plant to Enable Personalized Healthcare, Emerson’s Christian Berg provides a broader perspective of personalized healthcare and its challenges for the Life Sciences industry.
Sean Buckley and co-authors from Roche, Takeda, and BioPhorum author CGT [cell & gene therapy] Actors and Process Maps which highlight six common types of CGT showing how the pattern of actors and process blocks varies by therapy type.
The BioPhorum Operations Group (BPOG) established a digital plant maturity model (DPMM) for biopharmaceutical manufacturing to define stages of factory evolution “from simple paper-based plants through to the fully automated and integrated ‘adaptive plant’ of the future.” The model gives organizations a common tool for industry comparison and measurement of progress. It also provides a platform to facilitate collaboration within the life sciences industry and its technology providers.
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to stay up to date on the latest news, events and innovations that will help you face and solve your toughest challenges.
Just post a link to the entry and send us a quick note so we can share your work. Thank you very much.
Our Global Community
Emerson Exchange 365
This blog features expert perspectives from Emerson's automation professionals on industry trends, technologies, and best practices. The information shared here is intended to inform and educate our global community of users and partners.